APA

Hartnett J. C., Barnett S. F., Bilodeau M. T., Defeo-Jones D., Hartman G. D., Huber H. E., Jones R. E., Kral A. M., Robinson R. G. & Wu Z. (20080609). Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors. : Bioorganic & medicinal chemistry letters.

Chicago

Hartnett John C, Barnett Stanley F, Bilodeau Mark T, Defeo-Jones Deborah, Hartman George D, Huber Hans E, Jones Raymond E, Kral Astrid M, Robinson Ronald G and Wu Zhicai. 20080609. Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors. : Bioorganic & medicinal chemistry letters.

Harvard

Hartnett J. C., Barnett S. F., Bilodeau M. T., Defeo-Jones D., Hartman G. D., Huber H. E., Jones R. E., Kral A. M., Robinson R. G. and Wu Z. (20080609). Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors. : Bioorganic & medicinal chemistry letters.

MLA

Hartnett John C, Barnett Stanley F, Bilodeau Mark T, Defeo-Jones Deborah, Hartman George D, Huber Hans E, Jones Raymond E, Kral Astrid M, Robinson Ronald G and Wu Zhicai. Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors. : Bioorganic & medicinal chemistry letters. 20080609.